Biotech Values

[jq1234]

Lilly's Basal Insulin Peglispro Shows Superiority in HbA1c Reduction Compared to Insulin Glargine in Three Phase III Trials in Patients with Type 2 Diabetes

[Peglispro is LY2605541 BI returned to LLY after ph2. Safety issues remain in ph3.]

In all three clinical trials, more patients taking BIL had an increase in the liver enzyme ALT (alanine aminotransferase) to greater than three times the upper limit of the normal range compared with those taking insulin glargine. No cases of severe drug-induced liver injury (Hy's Law) occurred in these studies.

http://boardvote.com/symbol/LLY/communique/643820